ReviewCancers2022
Current Standards in the Management of Early and Locally Advanced Cervical Cancer: Update on the Benefit of Neoadjuvant/Adjuvant Strategies.
Review in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 28 citations in OpenAlex.
- Article
- Adherence to Survivorship Care Visits in Patients With Cervical Cancer in Botswana.JCO global oncology · 2026Observational
- Integrated computational screening of FDA-approved anticancer drugs as novel HPV-16 E6 inhibitors in cervical cancer.Scientific reports · 2026Article
- An "off-on" CdTe QDs fluorescent nanosensor for detecting apoptosis in osteosarcoma and evaluating chemotherapy response.Scientific reports · 2026Article
- PRDM1 Is Associated with Chemoradiotherapy-Associated Enrichment of Adaptive NK Cells in Cervical Cancer.Computational and structural biotechnology journal · 2026Article
- Association of comorbidity burden with initial treatment allocation in older women with gynecologic cancer: a retrospective cohort study.Frontiers in medicine · 2026Article
- Multidimensional assessment of urinary dysfunction and quality of life after cervical cancer treatment: a multicenter study integrating urodynamics and patient-reported outcomes.Frontiers in oncology · 2026Article
- Cellular Immunotherapy for Cervical Cancer: Next Therapeutics Frontiers.Oncology research · 2026Review
- The role of long non-coding RNAs in therapy resistance of cervical cancer and therapeutic potential.Frontiers in cell and developmental biology · 2026Review
- Neoadjuvant Paclitaxel-Carboplatin Followed by Concurrent Chemoradiotherapy versus Concurrent Chemoradiotherapy Alone in Locally Advanced Cervical Cancer.International journal of women's health · 2026Article
- MIR155HG promotes metastasis and cisplatin resistance of cervical cancer cells by regulating the miR-409-3p and ZEB1 axis.Scientific reports · 2025Article
- Evaluating the Cost-Effectiveness of Cervical Cancer Screening and Treatment in Western Romania.Current oncology (Toronto, Ont.) · 2025Article
- Efficacy of induction chemotherapy during the COVID-19 pandemic for treatment of locally advanced cervical cancer in Botswana.Gynecologic oncology · 2025Observational
- Article
- The promise of PD1/PDL1 targeted immunotherapy in locally advanced cervical cancer: a game-changer for patients outcome?Frontiers in immunology · 2025Review
- A Retrospective Study of Clinicopathological Features and Survival Outcomes in 305 Surgically Treated Patients with Stage IB-IIA Cervical Squamous Cell Carcinoma.International journal of women's health · 2025Article
- Prevalence and contributing factors of anemia in patients with gynecological cancer: a retrospective cohort study.Scientific reports · 2024Article
- Phase I Trial of First-line Bintrafusp Alfa in Patients with Locally Advanced or Persistent/Recurrent/Metastatic Cervical Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2024Article
- Efficacy and safety of consolidation chemotherapy after adjuvant therapy in stage IB-IIA cervical cancer patients with risk factors: a retrospective single-center study.Frontiers in oncology · 2024Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Globally, cervical cancers continue to be one of the leading causes of cancer-related deaths. The primary treatment of patients with early-stage disease includes surgery or radiation therapy with or without chemotherapy. The main challenge in treating these patients is to maintain a curative approach and limit treatment-related morbidity. Traditionally, inoperable patients are treated with radiation therapy solely and operable patients undergo upfront surgery followed by adjuvant (chemo) radiotherapy in cases with poor histopathological prognostic features. Patients with locally advanced cervical cancers are treated with concurrent chemoradiotherapy followed by an image-guided brachytherapy boost. In these patients, the main pattern of failure is distant relapse, encouraging intensification of systemic treatments to improve disease control. Ongoing trials are evaluating immunotherapy in locally advanced tumours following its encouraging efficacy reported in the recurrent and metastatic settings. In this article, clinical evidence of neoadjuvant and adjuvant treatments in cervical cancer patients is reviewed, with a focus on potential strategies to improve patients' outcome and minimize treatment-related morbidity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.